Phenylalanine 193 in extracellular loop 2 of the β_2 -adrenergic receptor coordinates β -arrestin interaction

Michael Ippolito, Francesco De Pascali, Asuka Inoue and Jeffrey L. Benovic*

Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA (M.I., F.D.P., J.L.B.)

Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.)

Running Title: Extracellular control of signaling bias at the β_2 AR

***Address correspondence to:**

Jeffrey L. Benovic, Ph.D.

Department of Biochemistry and Molecular Biology, Thomas Jefferson University

233 S. 10th St., 926 BLSB, Philadelphia, PA 19107, USA

Phone: 215-503-4607; e-mail: jeffrey.benovic@jefferson.edu

Number of text pages: 28

Number of tables: 1

Number of figures: 4

Number of references: 44

Number of words in the Abstract: 169

Number of words in the Introduction: 510

Number of words in the Discussion: 826

List of Abbreviations: β_1 AR, β_1 -adrenergic receptor; β_2 AR, β_2 -adrenergic receptor; BRET, bioluminescence resonance energy transfer; cAMP, 3',5'-cyclic adenosine monophosphate; DMEM, Dulbecco's modified Eagle's medium; ECL, extracellular loop; FBS, fetal bovine serum; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; ISO, isoproterenol; PBS, phosphate buffered saline; pEC₅₀, negative log of the half-maximal effective concentration; pIC₅₀, negative log of the half-maximal inhibitory concentration; TM, transmembrane domain; WT, wild-type

Abstract

G protein-coupled receptors (GPCRs) transduce a diverse variety of extracellular stimuli into intracellular signaling. These receptors are the most clinically productive drug targets at present. Despite decades of research on the signaling consequences of molecule-receptor interactions, conformational components of receptor-effector interactions remain incompletely described. The β_2 -adrenergic receptor (β_2 AR) is a prototypical and extensively studied GPCR that can provide insight into this aspect of GPCR signaling thanks to robust structural data and rich pharmacopeia. Using BRET-based biosensors, second messenger assays, and biochemical techniques we characterize the properties of β_2 AR-F193A. This single point mutation in extracellular loop 2 of the β_2 AR is sufficient to intrinsically bias the β_2 AR away from β -arrestin interaction and demonstrates altered regulatory outcomes downstream of this functional selectivity. This study highlights the importance of extracellular control of intracellular response to stimuli and suggests a previously undescribed role for the extracellular loops of the receptor and the extracellular pocket formed by transmembrane domains 2, 3, and 7 in GPCR regulation that may contribute to biased signaling at GPCRs.

Significance Statement

The role of extracellular GPCR domains in mediating intracellular interactions is not well understood. Here we characterized the effects of extracellular loop mutations on agonist-promoted interactions of GPCRs with G protein and β -arrestin. Our studies reveal that F193 in extracellular loop 2 in the β_2 -adrenergic receptor mediates interactions with G protein and β -arrestin with a biased loss of β -arrestin binding. These results provide new insight on the role of the extracellular domain in differentially modulating intracellular interactions with GPCRs.

Introduction

G protein-coupled receptors (GPCRs) are well appreciated to be clinically important therapeutic targets and as such have been the subject of intense study for many decades (Jacobson, 2015). The β_2 -adrenergic receptor (β_2 AR) has served as an exemplar model for GPCR function, structure, and signaling paradigms as more was understood about these receptors' complex pharmacology and interactome (Pierce *et al.*, 2002). Canonically, when the β_2 AR is activated by an exogenous agonist or endogenous catecholamine, the receptor undergoes conformational changes that promote activation of the heterotrimeric G_s protein to initiate downstream signaling. The activated receptor is then phosphorylated by G protein-coupled receptor kinases (GRKs) which promotes recruitment of β -arrestins to facilitate receptor uncoupling from G_s (desensitization), receptor endocytosis and β -arrestin-mediated signaling (Krupnick and Benovic, 1998; Tan *et al.*, 2018). β_2 AR ligands comprised of agonists, antagonists, inverse agonists, biased agonists and other pharmacological agents have been discovered and have been important tools in understanding the functional aspects of modulating β_2 AR signaling (Salon *et al.*, 2011). Additionally, due to advances in biophysical characterization of GPCRs, the structural features of these classes of ligands have been elucidated to some extent (Manglik and Kobilka, 2014; Latorraca *et al.*, 2017). While both the pharmacological tools and structural information around the β_2 AR is robust, it remains incomplete (Capper and Wacker, 2018), and the mechanism through which the receptor transitions from G protein interactions to GRKs to β -arrestins is unclear.

Previous studies have demonstrated the key role that the GPCR extracellular domains play in GPCR signaling outcomes, and several allosteric modulators of GPCRs have been discovered to occupy these regions (Strachan *et al.*, 2014; Thal *et al.*, 2018; Bermudez and Bock,

2019). In the β_2 AR, the extracellular vestibule, a region occupying space above the endogenous orthosteric ligand binding site, is a mediator of ligand entry and exit and activation dynamics (Dror *et al.*, 2011). This pocket has been modeled to create a metastable energy barrier that must be overcome to achieve ligand binding in the orthosteric site (Dror *et al.*, 2011). This occurs at a steric “gate” formed by phenylalanine 193 (F193) in extracellular loop 2 (ECL2) and tyrosine 308 (Y308) (Ballesteros-Weinstein number 7.35) in TM7 that caps this site (Ballesteros and Weinstein, 1995). The position of Y308 has been implicated in G protein interaction in corresponding residues in other GPCRs, and it has been suggested by molecular dynamics that F193 is a “functional hotspot” in the β_2 AR (Masureel *et al.*, 2018; Nivedha *et al.*, 2018). In this study, we examined the role of this entry barrier in receptor function by disrupting the steric gate in the extracellular vestibule through mutagenesis and subsequent characterization.

Understanding the molecular mechanisms of the transition from activation of G proteins to downstream regulation is paramount to developing the next generation of GPCR therapeutics. Here we show that disruption of the steric gate at the extracellular vestibule substantially biases β_2 AR signaling toward G protein activation by inhibiting receptor phosphorylation and interaction with β -arrestin. This work provides insight into the molecular features of β_2 AR bias and subsequent cellular responses and provides insight into differential bias between adrenergic receptor family members.

Materials and Methods

Cell culture. HEK 293 cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM) containing 10% fetal bovine serum (FBS) and 12.5 mM HEPES, pH 7.2. β_2 AR and β -arrestin1/2 triple-KO HEK 293 cells (hereafter simply referred to as β_2 AR KO) (Cahill *et al.*, 2017) were

maintained in DMEM containing 10% FBS and 12.5 mM HEPES, pH 7.2 and penicillin-streptomycin. Cells were incubated at 37 °C in a humidified incubator with 5% CO₂.

cAMP measurement. To eliminate endogenous adrenergic receptor mediated responses, β_2 AR-HEK 293 KO cells were used. The cells were transiently transfected with WT β_2 AR or β_2 AR-F193A, seeded in poly-L-lysine coated 24-well plates, incubated at 37 °C, and treated with indicated concentrations of ISO for 10 minutes. Cells were then lysed in 0.1 M HCl for 20 minutes at room temperature. cAMP levels were measured using the Cayman Chemical Cyclic AMP EIA kit following the manufacturer's instructions.

G_s recruitment by Bioluminescent Resonance Energy Transfer (BRET) assay. HEK 293 cells were transiently co-transfected with wild-type (β_2 AR or β_1 AR) or mutated (β_2 AR-F193A or β_1 AR-F201A) receptor C-terminally fused with BRET donor RlucII and the mini-G protein BRET acceptor NES-Venus-mG_s (Wan et al., 2018). Forty-eight hours post-transfection, medium was removed, and cells were incubated with the indicated concentration of ISO in the presence of 5 μ M Renilla luciferase substrate coelenterazine H for 15 minutes. BRET was measured using a Tecan Infinite F500 microplate reader. BRET ratios were calculated as the light emitted by the Venus acceptor divided by the total light emitted by the RLucII donor.

Analysis of β -arrestin2 binding to the β_2 AR and β_1 AR using BRET. HEK 293 cells were transfected with wild type or mutant pcDNA- β -arrestin2-GFP10 and either pcDNA3- β_2 AR-RlucII, pcDNA3- β_2 AR-F193A-RlucII, pcDNA3- β_1 AR-RlucII, or pcDNA3- β_1 AR-F201A-RlucII using X-tremegene HP9 complexed in serum-free optiMEM. 24 hours after transfection, cells

were replated at 100,000 cells per well in an opaque, poly-L-lysine coated 96-well plate and incubated overnight at 37 °C. Coelenterazine 400a was added to cells prior to agonist stimulation. BRET was measured using a Tecan Infinite F500 microplate reader and BRET ratios were calculated as the light emitted by the GFP10 acceptor divided by the total light emitted by the RLucII donor. To evaluate the role of receptor phosphorylation in β -arrestin binding, a constitutively active β -arrestin2 insensitive to the phosphorylation state of the β_2 AR was generated by mutation of Ile386, Val387 and Phe388 to alanine (AAA mutant) as previously described (Clever J. *et al.*, 2002) and then analyzed for binding to WT and mutant β_2 AR as described above.

Cell membrane preparation. HEK 293 cells were transfected with β_2 AR WT or β_2 AR-F193A using X-tremegene HP9 complexed in serum-free optiMEM. After 48 hours, media was aspirated and the cells were lysed on ice in 50 mM Tris-HCl, pH 7.7 for 10 minutes. Cells were then scraped and pelleted by centrifugation at 1000 rpm for five minutes. The pellet was washed with 50 mM Tris-HCl, pH 7.7 and passed through a 22-gauge syringe five times. Lysed cells were spun at 27,000 x g for 10 minutes and the pellet was resuspended in buffer containing 15 mM Tris-HCl, pH 7.4, 120 mM sodium chloride, 5.4 mM potassium chloride, 1.8 mM calcium chloride, and 5 mM glucose. Determination of total membrane protein concentration was determined by Bradford assay.

Competition binding assay. 60 μ g of cell membrane protein were incubated with 0.5 nM [3 H]dihydroxyalprenolol and the indicated concentrations of ISO in a volume of 1 ml. The mixture was incubated at 25°C for 1 h and then filtered over GF/C glass fiber filters soaked in

0.05% polyethylenimine. The filters were washed 3 times with ice cold Tris buffered saline. Bound radioactivity was measured by liquid scintillation counting and expressed in counts per minute.

In-cell β_2 AR phosphorylation. HEK 293 cells seeded into poly-L-lysine coated 6-well plates were transiently transfected with FLAG-tagged β_2 AR WT or β_2 AR-F193A and incubated at 37 °C. After 48 hours, cells were incubated with 0, 1 or 100 μ M ISO for 10 minutes and then rinsed with phosphate buffered saline (PBS), scraped in lysis buffer on ice, and sonicated. Lysates were immunoprecipitated using rabbit polyclonal anti-FLAG and Protein G agarose beads. Immunoprecipitated proteins were separated by SDS-PAGE and analyzed by western blot using a β_2 AR phospho-specific antibody or FLAG antibody.

Mutagenesis. β_2 AR-F193A and β_1 AR-F201A mutants were created with the Q5 Site-Directed Mutagenesis Kit (New England Biolabs) according to manufacturer's protocol.

Receptor internalization. HEK 293 cells transiently transfected with FLAG- β_2 AR WT or FLAG- β_2 AR-F193A were seeded into poly-L-lysine coated 24-well plates and incubated at 37 °C. Cells were stimulated with 1 μ M ISO for 0-60 minutes. Cells were then fixed on ice and processed for cell surface ELISA with polyclonal anti-FLAG primary antibody, anti-rabbit HRP secondary antibody, and incubation with (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) (ABTS). Absorbance was then measured on a plate reader at 405 nm.

Functional desensitization in HEK 293 cells. β_2 AR KO HEK 293 cells were transiently transfected with pcDNA- β -arrestin2-GFP10 and either β_2 AR WT or β_2 AR-F193A and were seeded in poly-L-lysine coated 24-well plates and incubated at 37 °C. Cells were stimulated with 1 μ M ISO for 30 minutes. Cells were washed 3 times with PBS and incubated with various concentrations of ISO for 10 minutes at 37 °C. Cells were then lysed in 0.1 M HCl for 20 minutes at room temperature and cAMP levels were measured using the Caymen Chemical Cyclic AMP EIA kit following the manufacturer's instructions.

Extracellular region alignment. Alignment of the extracellular regions was done with Clustal Omega multiple sequence alignment tool (Madeira *et al.*, 2019) and residue sequences of these regions were obtained from UniProt.

Quantification and statistical analysis. All statistical analyses were produced using Prism 8.0 (GraphPad Software). All data are expressed as the mean $\pm$ standard deviation (SD) from at least 3 independent experiments, unless otherwise stated in the figure legend. For normalizations, the values of all replicates were divided by the mean of isoproterenol-induced maximal responses and multiplied by 100 for any given read-out. Comparison of pEC₅₀s, pIC₅₀ and maximal efficacies were assessed by unpaired t-test and considered statistically significant when $p < 0.05$. Stimulus inactivation was quantitated as previously described (Ostrom and Ehlert, 1996).

Results

Mutagenesis of the extracellular region of the β_2 AR reveals F193 as a key determinant of β -arrestin interaction.

Recent work in our lab has identified a potential role for the extracellular vestibule in coordinating response to biased ligands. This extracellular region located above the orthosteric binding site of the receptor including extracellular loops 2 and 3 was used as a starting point to determine key residues for propagating a biased signaling profile (Fig. 1A). Generating point mutants around this site and subsequent evaluation by BRET revealed that isoproterenol (ISO)-promoted β_2 AR interaction with β -arrestin is robustly inhibited by the mutation of phenylalanine 193 to alanine (F193A) while mutation of other residues in ECL2 and ECL3 had modest effects (Fig. 1B). This suggests that F193 is a key residue involved in coordinating β -arrestin coupling to the β_2 AR.

Characterization of β_2 AR-F193A demonstrates intrinsic G protein bias

Figure 2A shows the alteration of the steric gate in β_2 AR-F193A (WT, gray spheres, F193A, yellow sticks). Given the previously hypothesized role of this residue as a functional hotspot (Nivedha *et al.*, 2018) and demonstrated inhibition of β -arrestin interaction by mutagenesis, we next characterized receptor function more broadly for this point mutant. Here we verify that β_2 AR-F193A shows substantial inhibition of agonist-promoted β -arrestin interaction as assessed by BRET, with a 280-fold right-shift in the ISO dose response (mean $\text{pEC}_{50} \pm \text{SD} = 7.71 \pm 0.29$ vs. 5.26 ± 0.11 , Fig. 2B and Table 1). To evaluate whether this phenotype was caused by reduced agonist binding, we performed competition binding assays with membranes harvested from cells expressing either WT β_2 AR or β_2 AR-F193A. In these studies, various concentrations of ISO were incubated with the receptor preparations in the presence of the tritiated β_2 AR antagonist,

[³H]dihydroxyalprenolol (Fig. 2C). It was found that both WT and mutant receptor show similar agonist binding profiles with a 2.8-fold right-shift in the IC₅₀ for the mutant receptor (mean pIC₅₀ ± SD = 5.89 ± 0.02 vs. 5.45 ± 0.03, unpaired t-test, p<0.05). Interestingly, this point mutation causes minimal ISO dose response shift for cAMP response (mean pEC₅₀ ± SD = 7.92 ± 0.47 vs. 7.86 ± 0.40) with no reduction in efficacy as measured by ELISA in β₂AR-KO HEK 293 cells transiently transfected with wild-type or mutant receptor (Fig. 2D, Table 1). However, it's worth noting that the basal level of cAMP at very low levels of ISO is greatly reduced for the F193A mutant compared to WT β₂AR (Fig. 2D). To control for the amplification of cellular cAMP, recruitment of mini-G_s by BRET was also performed. In these studies, a 20-fold right shift of mini-G_s recruitment was observed for the mutant receptor compared to wild-type (mean pEC₅₀ ± SD = 7.98 ± 0.55 vs. 6.67 ± 0.26, Fig. 2E, Table 1). It is possible that this effect is driven in part by intrinsic differences between endogenous WT G_s and the mini-G_s construct in addition to amplification effects in the cAMP measurements. Taken together, F193A is partially defective in mediating agonist promoted interactions of the β₂AR with both G_s and β-arrestin although it is clearly more disrupted in β-arrestin binding. To further confirm this, we performed a quantitation of the stimulus inactivation for the pathways considered as previously described by Ostrom and Ehlert, 1997. Such analysis estimates the apparent fractional loss in the receptor population that could account for the loss in function. The stimulus inactivation analysis revealed a decrease in the apparent efficacy only for β-arrestin2 recruitment to F193A vs the WT β₂AR (Table 1).

Downstream regulation of agonist activation is impaired for β₂AR-F193A

Typically, activation of the β₂AR stimulates the G_s-adenylyl cyclase-cAMP-PKA pathway and is coupled to regulatory processes associated with phosphorylation of the receptor by GRKs and β-

arrestin interaction (Hodavance *et al.*, 2016). These regulatory mechanisms are critical to the inhibition of β_2 AR signaling via receptor desensitization and β -arrestin-mediated internalization (Ferguson *et al.*, 1996; Goodman *et al.*, 1996; Nobles *et al.*, 2011). We evaluated these regulatory processes in the context of the intrinsically biased F193A mutant. Using an in-cell receptor phosphorylation assay, it was determined that GRK-mediated phosphorylation of Ser355/356 on the receptor C-tail is substantially inhibited for β_2 AR-F193A compared to wild-type even at very high concentrations of ISO (Fig. 3A and B). To determine whether the observed bias of β_2 AR-F193A was due to a difference in the conformational repertoire of the receptor or simply due to inefficient GRK coupling, we performed a BRET assay using a phosphorylation insensitive β -arrestin mutant carrying a triple alanine substitution in the C-tail of β -arrestin2 (AAA) as previously described (Clever *et al.*, 2002). ISO dose response curves were left-shifted 2-3-fold in the presence of AAA compared to WT β -arrestin2 for both WT and mutant receptor (Fig. 3C). This left shift is in line with previous studies showing that phosphorylation of the β_2 AR enhances the affinity of β -arrestin for the receptor by ~10-fold (Lohse *et al.*, 1992). It's also evident that the ISO promoted β -arrestin2 interaction was greatly reduced for β_2 AR-F193A compared to WT β_2 AR for both forms of β -arrestin examined (Fig. 3C). This indicates that the decreased capacity for β -arrestin interaction is at least partially due to a biased conformation of the receptor rather than simply reduced GRK phosphorylation or a general reduction in receptor efficacy.

We also examined agonist-promoted receptor internalization using a cell-surface ELISA. We found that β_2 AR-F193A was unresponsive to agonist promoted internalization relative to wild-type, with cell surface levels of β_2 AR-F193A unchanged up to 60 minutes post agonist

addition (Fig. 3D and E). These results support the loss of β -arrestin binding in this point mutant and demonstrates an altered regulatory phenotype when compared to WT β_2 AR.

Agonist promoted desensitization of cellular response to β -agonists is a known consequence of prolonged treatment that manifests downstream of GRK phosphorylation and β -arrestin binding (Gagnon *et al.*, 1998; Deshpande and Penn, 2006; Deshpande *et al.*, 2008). To evaluate whether β_2 AR-F193A was sensitive to this phenomenon, β_2 AR-KO cells transiently transfected with wild-type or F193A mutant were stimulated with ISO for 30 minutes, washed, and then re-stimulated with various doses of ISO to generate dose response curves for cAMP production. Relative to a control generated from cells that were not pre-treated with ISO, we observe a right-shift in the EC_{50} of ISO and decreased response in wild-type β_2 AR cells that is greatly diminished in cells expressing β_2 AR-F193A (Fig. 3F and G). These results suggest that the point mutant is insensitive to acute desensitization promoted by agonist treatment, and is consistent with the observation that receptor phosphorylation, β -arrestin binding and receptor internalization are inhibited for β_2 AR-F193A.

F193 represents a highly conserved ECL2 residue in class A GPCRs

Class A GPCRs like the β_2 AR represent the largest and most diverse GPCR subfamily (Venkatakrisnan *et al.*, 2019). This class of receptors, despite regulating varied physiological functions, share many evolutionarily conserved sequence motifs and activation/regulatory processes (Von Zastrow and Hanyaloglu, 2008; Filipek, 2019). An alignment of the extracellular regions of several β -adrenergic, adenosine, muscarinic acetylcholine, and dopamine receptors is shown in Fig. 4A. In the alignment it is apparent that a phenylalanine residue corresponding to

F193 in the β_2 AR (or tyrosine in the dopamine D2R) is conserved across several GPCR families and within GPCR family members.

To initially evaluate whether the observed extracellular control of receptor regulation was functionally conserved for other GPCRs, we evaluated G_s and β -arrestin interaction with the β_1 -adrenergic receptor (β_1 AR) using BRET. To do this, we generated the point mutant β_1 AR-F201A, the position that is analogous to β_2 AR-F193A (Fig. 4B). Comparisons between ISO stimulated wild-type β_1 AR and β_1 AR-F201A show an even greater reduction in β -arrestin interaction as compared to the β_2 AR-F193A with an ~10,000-fold shift in EC_{50} (Fig. 4C). Interestingly, this mutation also causes a substantial right shift in mini- G_s recruitment to the β_1 AR with an ~500-fold shift in EC_{50} (Fig. 4D). Due to the conservation of this residue in multiple receptor extracellular regions and functional consequences observed in the β_1 AR, it seems likely that this extracellular region coordinates control over intracellular signaling outcomes for other GPCRs.

Discussion

Biased signaling of GPCRs remains a promising avenue for clinical application that has yet unmet applications in areas of clinical need (Kenakin, 2018; Michel and Charlton, 2018). These span pathologies ranging from psychiatric disorders, airway disease, metabolic disorders, cardiovascular disease, and cancer. Untangling physiological processes from specific signaling pathways may provide a path to new generations of therapeutics with enhanced clinical benefit and fewer side effects. The molecular determinants of biased signaling through various class A GPCRs has been a subject of increased investigation in recent studies (Rahmeh *et al.*, 2012; Choi *et al.*, 2018; Lamichhane *et al.*, 2020; Suomivuori *et al.*, 2020). Many labs have provided insight

into this signaling paradigm in different systems, including the dopamine D2 receptor, the angiotensin II receptor type 1, and the β_2 AR (Carr III *et al.*, 2014; Sanchez-Soto *et al.*, 2020; Wingler *et al.*, 2020). Functional selectivity in activation of these receptors and others is now widely accepted as an intrinsic feature of GPCR signaling, but there is less agreement about how these signaling paradigms are achieved.

Previous work has shown the importance of the extracellular loops of β_2 AR in mediating ligand specificity and dynamic changes, but this hasn't been extended to a comprehensive analysis of signaling profiles (Ahuja *et al.*, 2009; Bokoch *et al.*, 2010; Baker *et al.*, 2015). A very recent study examined the role of transmembrane domain 7 (TM7) of the β_2 AR using an *in vitro* single molecule fluorescence system to examine the role of conformational exchange kinetics on β -arrestin bias (Lamichhane *et al.*, 2020). In this study, TM7 conformers were demonstrated to diverge for balanced and arrestin-biased agonists of β_2 AR, indicating a role for TM7 in arrestin coupling. Additionally, molecular dynamics simulations of β_2 AR have implicated F193 as an allosteric propagator of conformational changes through TM2 and TM7 and suggested a role for this residue in coordinating an allosteric pipeline during active state transitions (Bhattacharya and Vaidehi, 2014). Consistent with previous studies, we demonstrate that this region is able to stabilize a biased conformation of the receptor and could act as a switch propagating conformational changes to facilitate either G protein, GRK, and/or β -arrestin interaction. By mutating residues in the extracellular domains of β_2 AR, we were able to identify phenylalanine 193 on extracellular loop 2 as a powerful modulator of downstream protein-protein interaction.

Our findings are in agreement with the strong effect that mutation of F193 has on the ability of the β_2 AR to interact with GRKs and β -arrestins. A plausible mechanism for this is that transmembrane domain shifts are coordinated and propagated by residues at the extracellular

loops of the receptor, and that these transitions are disrupted in the mutant receptor. Here we find that mutation of F193 to an alanine is sufficient to right shift agonist promoted β -arrestin recruitment to β_2 AR over 200-fold while having a lesser detrimental effect on G_s binding and activation. This residue has also been characterized by molecular dynamics as forming a steric gate that represents the final major energy barrier to agonist binding at the orthosteric site (Dror *et al.*, 2011). In this work, we demonstrate that a point mutation at this energy barrier has little effect on agonist binding affinity, but greatly inhibits downstream regulation of the β_2 AR. This may suggest a role for dynamic features of ligand binding as mediators of ligand bias.

Despite large numbers of GPCR structures elucidated by crystallography and cryo-electron microscopy in recent years with a variety of pharmacological agents, a complete understanding of the structural transitions between G protein coupling, GRK interaction, and arrestin interaction has not been established. Understanding these transitions will provide a framework for improved drug design for targeting specific GPCR pathways. This work helps to elucidate the molecular mechanism through which biased signaling is propagated at adrenergic receptors. Our data are primarily focused around the β_2 AR although our work also demonstrates applicability to the β_1 AR and suggest that the role of the extracellular regions in signaling bias may be applicable to many class A GPCRs. Previous studies have used similar approaches for other GPCRs including the dopamine D2 receptor and allosteric modulation of the M2 muscarinic acetylcholine receptor (Croy *et al.*, 2014; Sanchez-Soto *et al.*, 2020).

In summary, this study demonstrates that extracellular control over signaling transitions from G protein pathways to regulatory pathways is a feature of the β_2 AR, and it may have broader implications for other class A GPCRs. F193 in extracellular loop 2 is a key determinant of β_2 AR signaling activity, and mutation of this residue is sufficient to generate a receptor that is

intrinsically biased away from β -arrestin. Our data implicate transducer stoichiometry-independent achievement of signaling bias. Additionally, the pocket formed by TMs 2, 3 and 7 and ECL2 and 3 functions as a regulatory domain that can both positively or negatively regulate β -arrestin interaction with the β_2 AR. Ultimately, this will provide a broader context through which to evaluate the pharmacological properties of novel β_2 AR ligands and inform drug design for biased ligands.

Acknowledgements

We thank Dr. Michel Bouvier for providing pcDNA- β -arrestin2-GFP10 and pcDNA3- β_2 AR-RlucII and Dr. Nevin A. Lambert for the NES-Venus-mG_s construct.

Authorship contributions:

Participated in research design: Ippolito, De Pascali, and Benovic

Conducted experiments: Ippolito, and De Pascali

Contributed new reagents or analytical tools: Inoue

Performed data analysis: Ippolito, De Pascali

Contributed to the writing of the manuscript: Ippolito, De Pascali, Inoue, Benovic

References

- Ahuja S, Hornak V, Yan ECY, Syrett N, Goncalves JA, Hirshfeld A, Ziliox M, Sakmar TP, Sheves M, Reeves PJ, Smith SO, and Eilers M (2009) Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. *Nat Struct Mol Biol* **16**: 168-175.

- Baker JG, Proudman RGW, and Hill SJ (2015) Salmeterol's extreme β_2 selectivity is due to residues in both extracellular loops and transmembrane domains. *Mol Pharmacol* **87**: 103-120.
- Ballesteros JA, and Weinstein H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods Neurosci* **25**: 366-428.
- Bermudez M, and Bock A (2019) Does divergent binding pocket closure drive ligand bias for class A GPCRs? *Trends Pharmacol Sci* **40**: 236-239.
- Bhattacharya S, and Vaidehi N (2014) Differences in allosteric communication pipelines in the inactive and active states of a GPCR. *Biophys J* **107**: 422-434.
- Bokoch MP, Zou Y, Rasmussen SGF, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi H-J, Thian FS, Kobilka TS, Puglisi JD, Weis WI, Pardo L, Prosser RS, Mueller L, and Kobilka BK (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. *Nature* **463**: 108-112.
- Cahill TJ, Thomsen ARB, Tarrasch JT, Plouffe B, Nguyen AH, Yang F, Huang LY, Kahsai AW, Bassoni DL, Gavino BJ, Lamerdin JE, Triest S, Shukla AK, Berger B, Little J, Antar A, Blanc A, Qu CX, Chen X, Kawakami K, Inoue A, Aoki J, Steyaert J, Sun JP, Bouvier M, Skiniotis G, and Lefkowitz RJ (2017) Distinct conformations of GPCR- β -arrestin complexes mediate desensitization, signaling, and endocytosis. *Proc Natl Acad Sci USA* **114**: 2562-2567.
- Capper MJ, and Wacker D (2018) A complex story of receptor signalling. *Nature* **558**: 529-530.
- Carr III R, Du Y, Quoyer J, Panettieri RA, Janz JM, Kobilka BK, Benovic JL, Bouvier M, Kobilka BK, and Benovic JL (2014) Development and characterization of pepducins as Gs-

- biased allosteric agonists. *J Biol Chem* **289**: 35668-35684.
- Celver J, Vishnivetskiy SA, Chavkin C, and Gurevich VV (2002) Conservation of the phosphate-sensitive elements in the arrestin family of proteins. *J Biol Chem* **277**: 9043-9048.
- Choi M, Staus DP, Wingler LM, Ahn S, Pani B, Capel WD, and Lefkowitz RJ (2018) G protein-coupled receptor kinases (GRKs) orchestrate biased agonism at the β_2 -adrenergic receptor. *Sci Signal* **11**: eaar7084.
- Croy CH, Schober DA, Xiao H, Quets A, Christopoulos A, Felder CC, Lilly E, and Indiana CHC (2014) Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. *Mol Pharmacol* **86**: 106-115.
- Deshpande DA, and Penn RB (2006) Targeting G protein-coupled receptor signaling in asthma. *Cell Signal* **18**: 2105-2120.
- Deshpande DA, Theriot BS, Penn RB, and Walker JKL (2008) β -Arrestins specifically constrain β_2 -adrenergic receptor signaling and function in airway smooth muscle. *FASEB J* **22**: 2134-2141.
- Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, and Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. *Proc Natl Acad Sci U S A* **108**: 13118-13123.
- Ferguson SSG, Downey WE, Colapietro A-M, Barak LS, Marnett L, and Caron MG (1996) Role of β -arrestin in mediating agonist-promoted G protein-coupled receptor internalization. *Science* **271**: 363-366.
- Filipek S (2019) Molecular switches in GPCRs. *Curr Opin Struct Biol* **55**: 114-120.
- Gagnon AW, Kallal L, and Benovic JL (1998) Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the β_2 -adrenergic receptor. *J Biol Chem* **273**: 6976-6981.

- Goodman J, Krupnick JG, Santini F, Gurevich V V., Penn RB, Gagnon AW, Keen JH, and Benovic JL (1996) β -Arrestin acts as a clathrin adaptor in endocytosis of the β 2-adrenergic receptor. *Nature* **383**: 447-450.
- Hodavance SY, Gareri C, Torok RD, and Rockman HA (2016) G protein-coupled receptor biased agonism. *J Cardiovasc Pharmacol* **67**: 193-202.
- Jacobson KA (2015) New paradigms in GPCR drug discovery. *Biochem Pharmacol* **98**: 541-555.
- Kenakin T (2018) Is the quest for signaling bias worth the effort? *Mol Pharmacol* **93**: 266-269.
- Krupnick JG, and Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* **38**: 289-319.
- Lamichhane R, Liu JJ, White KL, Katritch V, Stevens RC, Wüthrich K, and Millar DP (2020) Biased signaling of the G-protein-coupled receptor β 2AR is governed by conformational exchange kinetics. *Structure* **28**: 371-377.
- Latorraca NR, Venkatakrishnan AJ, and Dror RO (2017) GPCR dynamics: Structures in motion. *Chem Rev* **117**: 139-155.
- Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey ARN, Potter SC, Finn RD, and Lopez R (2019) The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res* **47**: W636–W641.
- Manglik A, and Kobilka B (2014) The role of protein dynamics in GPCR function: insights from the β 2AR and rhodopsin. *Curr Opin Cell Biol* **27**: 136-143.
- Masureel M, Zou Y, Picard L-P, van der Westhuizen E, Mahoney JP, Rodrigues JPGLM, Mildorf TJ, Dror RO, Shaw DE, Bouvier M, Pardon E, Steyaert J, Sunahara RK, Weis WI, Zhang C, and Kobilka BK (2018) Structural insights into binding specificity, efficacy and bias of a β 2AR partial agonist. *Nat Chem Biol* **14**: 1059-1066.

- Michel MC, and Charlton SJ (2018) Biased agonism in drug discovery - is it too soon to choose a path? *Mol Pharmacol* **93**: 259-265.
- Nivedha AK, Tautermann CS, Bhattacharya S, Lee S, Casarosa P, Kollak I, Kiechle T, and Vaidehi N (2018) Identifying functional hotspot residues for biased ligand design in G-protein-coupled receptors. *Mol Pharmacol* **93**: 288-296.
- Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang T-Y, Bressler EA, Hara MR, Shenoy SK, Gygi SP, and Lefkowitz RJ (2011) Distinct phosphorylation sites on the β 2-adrenergic receptor establish a barcode that encodes differential functions of β -arrestin. *Sci Signal* **4**: ra51.
- Ostrom RS, and Ehlert FJ (1997) M₂ muscarinic receptor inhibition of agonist-induced cyclic adenosine monophosphate accumulation and relaxation in the guinea pig ileum. *J Pharmacol Exp Ther* **280**: 189-199.
- Pierce KL, Premont RT, and Lefkowitz RJ (2002) Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* **3**: 639-650.
- Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Baneres JL, Mouillac B, and Granier S (2012) Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. *Proc Natl Acad Sci U S A* **109**: 6733-6738.
- Salon JA, Lodowski DT, and Palczewski K (2011) The significance of G Protein-coupled receptor crystallography for drug discovery. *Pharmacol Rev* **63**: 901-937.
- Sanchez-Soto M, Verma RK, Willette BKA, Gonye EC, Moore AM, Moritz AE, Boateng CA, Yano H, Free RB, Shi L, and Sibley DR (2020) A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.

Sci Signal **13**: eaaw5885.

Strachan RT, Sun JP, Rominger DH, Violin JD, Ahn S, Rojas Bie Thomsen A, Zhu X, Kleist A, Costa T, and Lefkowitz RJ (2014) Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). *J Biol Chem* **289**: 14211-14224.

Suomivuori CM, Latorraca NR, Wingler LM, Eismann S, King MC, Kleinhenz ALW, Skiba MA, Staus DP, Kruse AC, Lefkowitz RJ, and Dror RO (2020) Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. *Science* **367**: 881-887.

Tan L, Yan W, McCorvy JD, and Cheng J (2018) Biased ligands of G protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential. *J Med Chem* **61**: 9841-9878.

Thal DM, Glukhova A, Sexton PM, and Christopoulos A (2018) Structural insights into G-protein-coupled receptor allostery. *Nature* **559**: 45-53.

Venkatakrishnan AJ, Ma AK, Fonseca R, Latorraca NR, Kelly B, Betz RM, Asawa C, Kobilka BK, and Dror RO (2019) Diverse GPCRs exhibit conserved water networks for stabilization and activation. *Proc Natl Acad Sci U S A* **116**: 3288-3293.

Von Zastrow M, and Hanyaloglu AC (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. *Annu Rev Pharmacol Toxicol* **48**: 537-568.

Wan Q, Okashah N, Inoue A, Nehmé R, Carpenter B, Tate CG, and Lambert NA (2018) Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. *J Biol Chem* **293**: 7466-7473.

Wingler LM, Skiba MA, McMahon C, Staus DP, Kleinhenz ALW, Suomivuori CM, Latorraca NR, Dror RO, Lefkowitz RJ, and Kruse AC (2020) Angiotensin and biased analogs induce

structurally distinct active conformations within a GPCR. *Science* **367**: 888-892.

Footnotes

Research reported in this publication was supported by National Institutes of Health awards R35GM122541 (JLB), R01HL136219 (JLB), P01HL114471 (JLB), T32GM100836 (MI) and F31HL139104 (MI), and utilized the MetaOmics Shared Resource at Sidney Kimmel Cancer Center at Jefferson Health supported by National Institutes of Health award P30CA056036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. AI was funded by KAKENHI 21H04791 from The Japan Society for the Promotion of Science (JSPS); the PRIME 20gm5910013, the LEAP JP20gm0010004 and the BINDS JP20am0101095 from the Japan Agency for Medical Research and Development (AMED), and the Uehara Memorial Foundation.

Financial Disclosure

No author has a conflict with the contents of this article.

FIGURE LEGENDS

Figure 1. Mutagenesis of extracellular loops 2 and 3. (A) Top view of β_2 AR showing the orthosteric binding site (yellow mesh) and allosteric region (blue mesh). Key residues forming the allosteric region are shown as sticks. (B) ISO dose response curve for β -arrestin binding to WT and β_2 AR ECL2 and ECL3 mutants as measured by BRET. HEK 293 cells co-transfected with β -arrestin2-GFP10 and indicated β_2 AR-RlucII wild-type or mutant constructs were incubated with Coelenterazine 400a for 2 minutes and then stimulated with indicated concentrations of ISO. Data for dose response curve was taken 12 minutes post ISO addition. n=3 independent experiments.

Figure 2. Characterization of β_2 AR-F193A. (A) ECL3 facing side view of β_2 AR. The orthosteric site gate comprised of Y308 and F193 is represented by gray spheres. The mutated gate of the F193A mutant is represented by yellow sticks. Endogenous β_2 AR agonist adrenaline is shown in the orthosteric binding pocket (light blue, from PDB: 4LDO). (B) ISO dose response curve for β -arrestin binding to β_2 AR wild-type and β_2 AR-F193A as measured by BRET. HEK 293 cells co-transfected with β -arrestin2-GFP10 and indicated β_2 AR-RlucII wild-type or β_2 AR-F193A-RlucII constructs were incubated with Coelenterazine 400a for 2 minutes and then stimulated with indicated concentrations of ISO. Data for dose response curve was taken 12 minutes post ISO addition. n=3 independent experiments. (C) [3 H]dihydroxyalprenolol competition curves for ISO. n=3 independent experiments. (D) Dose response curves for ISO promoted cAMP production by ELISA. β_2 AR-KO HEK 293 transiently transfected with β_2 AR-WT or β_2 AR-F193A were stimulated with the indicated concentrations of ISO for 10 minutes. Cells were lysed and cAMP

production was measured. n=3 independent experiments. (E) Dose response curves for ISO promoted mini-G_s recruitment by BRET. HEK 293 cells transiently transfected wild-type or mutated β_2 AR-RlucII and NES-Venus-mG_s were stimulated with the indicated concentrations of ISO for 15 minutes and BRET signal was measured. n=3 independent experiments.

Figure 3. GRK phosphorylation, receptor internalization and desensitization for wild-type and mutant β_2 AR. (A) Representative blot for agonist promoted phosphorylation of the β_2 AR. HEK 293 cells expressing FLAG- β_2 AR-WT or FLAG- β_2 AR-F193A were stimulated with 0, 1 μ M or 100 μ M ISO for 10 minutes. Cells were lysed and the FLAG- β_2 AR was immunoprecipitated. Phosphorylation at serines 355 and 356 was analyzed by western blot using a pSer^{355/356} antibody while total β_2 AR was measured using an anti-FLAG antibody. The western blot is representative of at least 3 independent experiments and is quantified in panel (B). (C) ISO dose response curve for WT or AAA β -arrestin binding to β_2 AR wild-type and β_2 AR-F193A as measured by BRET. HEK 293 cells co-transfected with β -arrestin2-GFP10 or β -arrestin2-AAA-GFP10 and indicated β_2 AR-RlucII wild-type or β_2 AR-F193A-RlucII constructs were incubated with Coelenterazine 400a for 2 minutes and then stimulated with indicated concentrations of ISO. Data for dose response curve was taken 12 minutes post ISO addition. n=3 independent experiments. (D) Effect of F193A mutation on agonist-promoted internalization of the β_2 AR. HEK 293 cells expressing FLAG- β_2 AR-WT or FLAG- β_2 AR-F193A were stimulated with 1 μ M ISO for up to 60 minutes. Cells were fixed and receptor surface expression was measured by ELISA. Loss of cell surface expression at 60 minutes is quantified in (E). n=3 independent experiments. HEK 293 cells expressing β_2 AR-WT (F) or β_2 AR-F193A (G) were desensitized by incubating with 1 μ M ISO, washing with PBS, and then re-stimulating with ISO at the indicated concentrations for

10 minutes. Cells were lysed and cAMP production was measured by ELISA. n=3 independent experiments.

Figure 4. Analysis of extracellular residues of class A GPCRs. (A) Multiple sequence alignment of several class A GPCRs. β AR= β -adrenergic receptor, AAR=adenosine receptor, DR=dopamine receptor, MR=muscarinic acetylcholine receptor. (B) Structural alignment of β_2 AR (tan) and β_1 AR (yellow, PDB: 7BTS). β_2 AR residue F193 and β_1 AR residue F201 are indicated by sticks. (C) β -arrestin recruitment to β_1 AR-WT and β_1 AR-F201A as measured by BRET. HEK 293 cells co-transfected with β -arrestin2-GFP10 and indicated β_1 AR-WT-RlucII or β_1 AR-F201A-RlucII constructs were incubated with Coelenterazine 400a for 2 minutes and then stimulated with indicated concentrations of ISO. Data was collected at 6 minutes post agonist addition. n=3 independent experiments. (E) Dose response curves for ISO promoted mini- G_s recruitment to β_1 AR by BRET. HEK 293 cells transiently transfected wild-type or mutated β_1 AR-Rluc and NES-Venus-mGs were stimulated with the indicated concentrations of ISO for 15 minutes and BRET signal was measured. n=3 independent experiments.

Table 1
Comparison of β_2 AR-WT and β_2 AR-F193A

Assay	<u>pEC₅₀ ± SD</u>					<u>Maximum</u>			
	WT	F193A	Shift	Significant		WT (%)	F193A (% WT)	Significant	SI (%)
Arrestin BRET	7.71 ± 0.29	5.26 ± 0.11	2.45	Y		100	56.4 ± 4.7	Y	60.8
cAMP	7.92 ± 0.47	7.86 ± 0.41	0.06	N		100	111.9 ± 4.1	N	98.4
mGs BRET	7.98 ± 0.55	6.67 ± 0.26	1.31	Y		100	102.2 ± 9.6	N	99.9

Comparison of β_2 AR-WT and β_2 AR-F193A across assays. pEC₅₀ values and maximum response relative to β_2 AR-WT are listed. Shift indicates the difference in pEC₅₀ values for β_2 AR-WT and β_2 AR-F193A. Significance for pEC₅₀ and maximum response was determined by t-test for n = 3 experiments. Stimulus inactivation indicates a comparison of agonist doses that promote equal response in WT and mutant receptor in each assay. This parameter was estimated as described previously (Ostrom and Ehlert, 1997). Briefly, equiactive ISO concentrations were compared between β_2 AR-WT and β_2 AR-F193A by interpolating equivalent β_2 AR-F193A responses from β_2 AR-WT dose response curves. The stimulus inactivation parameter denotes the apparent efficacy of β_2 AR-F193A compared to wild-type. SI - stimulus inactivation

Figure 1

B

Figure 2

Figure 3

Figure 4

A

Receptor:	Extracellular Residue Alignment																
β_2 AR	C	Y	-	-	-	-	A	N	E	T	C	C	D	F	F	F	T
β_1 AR	C	Y	-	-	-	-	N	D	P	K	C	C	D	F	F	V	T
β_3 AR	C	H	-	-	-	-	E	G	Q	V	A	C	L	F	F	E	D
AA2AR	C	G	-	-	-	-	E	G	Q	V	A	C	L	F	F	E	D
AA2BR	C	-	-	-	-	-	-	-	L	V	K	C	L	F	F	E	N
D2R	C	I	I	A	N	-	-	-	P	A	F	V	V	Y	Y	S	S
M1	C	Y	I	Q	F	L	S	Q	P	I	I	T	-	F	F	G	T
M2	C	Y	I	Q	F	F	S	N	A	A	V	T	-	F	F	G	T
M4	C	F	I	Q	F	L	S	N	P	A	V	T	-	F	F	G	T